Talimogene laherparepvec - Amgen

Drug Profile

Talimogene laherparepvec - Amgen

Alternative Names: AMG-678; IMLYGIC; JS1/34.5- /47-/GM-CSF; OncoVEX; OncoVEXGM-CSF; T-VEC

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioVex
  • Developer Amgen; BioVex; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Merck & Co; Roche; University of Iowa
  • Class Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase II Breast cancer; Soft tissue sarcoma
  • Phase I Colorectal cancer; Head and neck cancer; Liver cancer
  • No development reported Pancreatic cancer; Solid tumours

Most Recent Events

  • 01 Jun 2018 Interim adverse events and efficacy data from a phase II trial in Malignant melanoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ATS-2018)
  • 18 May 2018 University of California and Amgen withdraws a phase I trial in Bladder cancer prior to enrolment as the investigators prefer to pursue other studies (NCT03430687)
  • 19 Apr 2018 Amgen completes a phase II trial in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada and USA (Intratumoural) (NCT02014441)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top